Coenzyme q 10 and Fertility Outcome in Women With Clomiphene Resistant PCOS
NCT ID: NCT04302532
Last Updated: 2020-11-25
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
149 participants
INTERVENTIONAL
2020-07-01
2020-10-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Clomiphene
clomiphene citrate 150 mg once a day for 5 days
clomiphene citrate
ovulation induction drug
clomiphene and coenzyme q10
clomiphene citrate 150 mg once a day for 5 days and coenzyme q 10 120 mg each day
Coenzyme Q10
antioxidant used to decrease oxidative stress and improve fertility prospects
clomiphene citrate
ovulation induction drug
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Coenzyme Q10
antioxidant used to decrease oxidative stress and improve fertility prospects
clomiphene citrate
ovulation induction drug
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* All women were previously treated with 100 mg of CC daily for 5 days per cycle, for two to three cycles with persistent anovulation or ovulate with very thin endometrium \<5 mm at the time of hCG administration
Exclusion Criteria
* known autoimmune disorders
* prior treatment of endometriosis or surgery to reproductive tract
* prior history of pelvic inflammatory disease
* those with tubal factors and uterine factors as assessed on history and confirmed by normal hysterosalpingogram.
* Thyroid disorder as assessed by history examination and TSH level
* Patients with raised FSH
20 Years
35 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Karachi Medical and Dental College
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
samia husain
clinical investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Rubina Izhar
Role: STUDY_DIRECTOR
Aziz Medical Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Aziz medical center
Karachi, Sindh, Pakistan
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
1
Identifier Type: -
Identifier Source: org_study_id